Resolution on adoption of accounts and allocation of the company’s result

The annual general meeting resolved to adopt the income statement and balance sheet as well as the consolidated income statement and the consolidated balance sheet. The annual general meeting also resolved to distribute the company’s result in accordance with the proposal from the board of directors in the annual report meaning that no dividends are paid for the financial year 2021/2022 and that the available funds are carried forward.

Discharge from liability for the members of the board of directors and the CEO

The annual general meeting resolved to discharge the members of the board of directors and the CEO from liability for the financial year 2021/2022.

Election and remuneration of the board of directors and auditors

The annual general meeting resolved in accordance with the proposal from the Nomination Committee to re-elect Anders Månsson, Christer Fåhraeus, Linda Neckmar, Rajiv I. Modi, Per Ollermark and Per Svangren as members of the board of directors for the period until the end of the next annual general meeting. Christer Fåhraeus was elected as new Chairman of the board of directors. Anders Månsson had declined re-election as Chairman of the board of directors.

The annual general meeting further resolved that board remuneration shall be paid with SEK 250,000 to the Chairman of the board of directors and with SEK 100,000 to each of the other board members who are not permanent employees in the company.

The annual general meeting finally resolved in accordance with the proposal from the Nomination Committee to elect Deloitte AB as auditor and that remuneration to the auditor shall be paid in accordance with approved invoice. Deloitte AB has informed that the authorized public accountant Maria Ekelund will be the auditor in charge.

Resolution on instruction for the Nomination Committee

The annual general meeting resolved in accordance with the proposal from the Nomination Committee that a Nomination Committee shall be appointed before coming election and remuneration. The Nomination Committee shall be comprised of three members, representing the three largest registered owners in terms of votes as of 31 December 2022. Furthermore, an instruction for the Nomination Committee was adopted.

For further information, please contact:
Christer Fåhraeus
CEO, EQL Pharma AB (publ)

Phone: +46 (0) 705 – 60 90 00
E-mail: christer.fahraeus@eqlpharma.com
Website: www.eqlpharma.com

EQL Pharma AB (publ) in short

EQL Pharma AB specializes in developing and selling niche pharmaceuticals. The company currently has more than 20 niche generics (ie generics with limited competition apart from the reference pharmaceutical) approved in the Nordic markets and a couple of originals. In addition to these, there is a significant pipeline of mainly niche generics for launch in 2022 and beyond. The business is currently entirely focused on prescription pharmaceuticals, including hospital products, in the Nordic region and in selected European markets. EQL Pharma AB conducts its operations in Lund and is listed on the Spotlight Stock Market. EQL Pharma AB conducts extensive development work in collaboration with leading contract manufacturers and pharmaceutical companies in the EU and Asia, among others.